Fig. 1 · Structure

Documents & Downloads

Adefovir dipivoxil

Cat. No. A10039 CAS 142340-99-6

ntRT inhibitor

Adefovir dipivoxil is an orally-administered nucleotide analog reverse transcriptase inhibitor (ntRTI). It is used for treatment of hepatitis B and herpes simplex virus infection.

In Stock

Publications for Adefovir dipivoxil

2 publications citing this product

  1. Ryogo Shimizu, .et al. , Hepatol Commun, 2024, Jan 5;8(1):e0351 PMID: 38180972
  2. Kazumoto Murata, .et al. , Gut, 2018, Feb; 67(2): 362-371 PMID: 27789659

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
CCRF-CEM EC50 0.045 μM Antiviral activity against wild type HIV-1 3B infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis [PMID: 23603046]
CCRF-CEM EC50 0.062 μM Antiviral activity against wild type HIV-2 ROD infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis [PMID: 23603046]
HEK293 IC50 13.5 μM Inhibition of human OAT1 expressed in HEK293 cells assessed as P-amino hippuric acid uptake inhibition incubated for 10 mins by UPLC-MS/MS method [PMID: 31301948]
HEL EC50 0.2 μM Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis [PMID: 23603046]
HEL EC50 0.2 μM Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis [PMID: 23603046]
HEL EC50 0.2 μM Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis [PMID: 23603046]
HEL EC50 4 μM Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis [PMID: 23603046]
HepG2 2.2.15 CC50 > 400 μM Toxicity against human HepG2.2.15 cells infected with HBV after 72 hrs by MTT assay [PMID: 27458783]
HepG2 2.2.15 IC50 0.33 μM Antiviral activity against Hepatitis B virus infected HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis by real-time PCR [PMID: 19889538]
HepG2 2.2.15 IC50 0.48 μM Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as viral DNA level after 9 days by southern blot analysis 10.1007/s00044-011-9616-2
HepG2 2.2.15 IC50 0.58 μM Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 9 days by RT-PCR analysis 10.1007/s00044-011-9616-2
HepG2 2.2.15 EC50 0.96 μM Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication incubated for 2 days followed by wash out measured after 10 days by RT-PCR analysis [PMID: 22305613]
HepG2 2.2.15 EC50 1.5 μM Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization [PMID: 20117930]
HepG2 2.2.15 EC50 1.8 μM Antiviral activity against 3TC-resistant HBV with polymerase M204V mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization [PMID: 20117930]
HepG2 2.2.15 EC50 2 μM Antiviral activity against 3TC-resistant HBV with polymerase M204I mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization [PMID: 20117930]
HepG2 2.2.15 EC50 2.1 μM Antiviral activity against 3TC-resistant HBV with polymerase L180M mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization [PMID: 20117930]
HepG2 2.2.15 EC50 2.2 μM Antiviral activity against 3TC-resistant HBV with polymerase LMMV mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization [PMID: 20117930]
HepG2 2.2.15 CC50 438.92 μM Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 12 hrs followed by replacement of fresh medium containing compound and measured after 2 days by CCK-8 assay [PMID: 31301948]

18 records · Scroll to view more

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 142340-99-6
Applications ntRT inhibitor
Formula C20H32N5O8P
Molecular Weight 501.5
Synonyms Bis-POM PMEA; Preveon; Hepsera
SMILES
CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 85 mg/mL (169.5 mM)
Water Insoluble
Ethanol 85 mg/mL (169.5 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Publications

2 publications citing this product

  1. Ryogo Shimizu, .et al. , Hepatol Commun, 2024, Jan 5;8(1):e0351 PMID: 38180972
  2. Kazumoto Murata, .et al. , Gut, 2018, Feb; 67(2): 362-371 PMID: 27789659

Added to your cart

View Cart Checkout
Loading...